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OBJECTIVES The aims of the present study were to assess 1) the effect of 8-Cl-cAMP (cyclic-39-59-
adenosine monophosphate) on vascular smooth muscle cell (VSMC) proliferation in vitro and
2) the efficacy of systemic administration of 8-Cl-cAMP on neointimal formation after
balloon injury in vivo.
BACKGROUND Neointimal formation after vascular injury is responsible for restenosis after arterial stenting.
Recently, 8-Cl-cAMP, a cAMP analogue that induces growth arrest, has been safely
administered in phase I studies in humans.
METHODS The effect of 8-Cl-cAMP on cell proliferation was first assessed on SMCs in vitro. To study
the effects of cAMP in vivo, balloon injury was performed in 67 rats using a 2F Fogarty
balloon catheter.
RESULTS The 8-Cl-cAMP markedly inhibited VSMC proliferation in vitro, reduced protein kinase A
(PKA) RIa subunit expression, and induced PKA RIIb subunit expression. In addition,
8-Cl-cAMP reduced, in a dose-dependent manner, neointimal area and neointima/media
ratio after balloon injury. The proliferative activity, assessed by proliferating nuclear cell
antigen immunostaining, revealed a reduction of proliferative activity of VSMCs in vivo in
the 8-Cl-cAMP group. Moreover, the systemic administration of 8-Cl-cAMP did not affect
renal function, blood pressure and heart rate.
CONCLUSIONS We conclude that 8-Cl-cAMP potently inhibits VSMC proliferation in vitro and reduces
neointima formation by balloon injury in vivo after systemic administration. These data may
have a clinical relevance in designing future strategies to prevent restenosis after arterial
stenting and perhaps after percutaneous transluminal coronary angioplasty. (J Am Coll
Cardiol 2000;36:288–93) © 2000 by the American College of Cardiology
Although stent deployment has been shown to reduce
restenosis rate compared with balloon angioplasty (1,2),
in-stent restenosis is a significant and growing clinical
problem. It is now well established that vascular smooth
muscle cell (VSMC) proliferation plays a major role in the
restenotic process after arterial stenting (3,4) and contrib-
utes to restenosis after balloon angioplasty (5,6). The
intracellular molecular mechanisms responsible for VSMC
growth regulation are now well known and are linked with
the ras pathway (7) and the cAMP–PKA (cyclic-39-59-
adenosine monophosphate–protein kinase A) intracellular
signaling (8). The cAMP signaling regulates an enormous
variety of cellular processes (9–14). We have previously
demonstrated that local delivery of 8-bromo-cAMP, using
pluronic gel as a vehicle and applied at the time of injury on
the external surface of the treated vessel, is able to prevent
neointima formation after vascular injury (8). However, the
method used in our previous study (8) is not clinically
feasible in percutaneous balloon dilation procedures and no
data are available regarding the effects of systemic cAMP
analogue administration on VSMC proliferation rate and
neointima formation after balloon injury in vivo.
Recently, 8-Cl-cAMP has been investigated as a new
potential anticancer agent in humans (15). The 8-Cl-cAMP
is a site-selective cAMP analogue able to modulate cAMP-
dependent PKA activity at micromolar concentration
(16,17). The PKA is present in eukaryotic cells as two
different isoforms, PKAI and PKAII, which have identical
catalytic subunits but different regulatory subunits (RI in
PKAI and RII in PKAII) (18,19). The 8-Cl-cAMP is able
to discriminate between the two cAMP binding sites
present on RI and RII, to modulate the intracellular levels of
those regulatory subunits at micromolar concentration, and
to arrest cell proliferation by causing down-regulation of RI
and up-regulation of RII at transcriptional level in several
cell types (16,18,20–25). No data are available regarding the
effect of 8-Cl-cAMP on VSMC proliferation. For its high
selectivity and its pharmacokinetics, 8-Cl-cAMP can be
used for systemic administration at low doses. In this regard,
it should be pointed out that neointimal growth triggered by
interventional coronary or peripheral procedures is spatially
and temporally limited. These features may represent an
obvious advantage using antiproliferative agents and can
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allow the use of an intermittent exposure regimen of
8-Cl-cAMP administration. Accordingly, the aims of the
present study were to assess the effects of 8-Cl-cAMP on
VSMC proliferation in vitro, RI-a and RII-b expression.
The efficacy of 8-Cl-cAMP on neointima formation in-
duced by balloon injury in vivo was also assessed.
METHODS
Cell culture. To study the effect of 8-Cl-cAMP VSMC
proliferation in vitro smooth muscle cells (A10, thoracic
aorta, rat) were used. Cells were grown in monolayers at
37°C in a humidified atmosphere at 95% air CO2 in 10%
FCS–DMEM (fetal calf serum–Dulbecco’s modified Ea-
gle’s medium) with 4 mmol/liter L-glutamine, 4.5 g/liter
glucose, and 1.0 mmol/liter sodium pyruvate. For growth
inhibition experiments, 2 3 104 cells were plated into
35-mm plates and grown in DMEM 10% FCS in the
presence of 1 mmol/liter, 5 mmol/liter, and 10 mmol/liter
8-Cl-cAMP, or in the absence of the same (control). Cell
number in both conditions was assessed every 48 h for six
days.
Western blotting. The VSMCs from rat aorta were used
to test the effect of 1 mmol/liter, 5 mmol/liter, and 10
mmol/liter 8-Cl-cAMP on expression of regulatory subunits
of PKAI. Western blotting was performed as described
previously (23). Mouse monoclonal antibodies raised
against anti-RIa, anti-RIIb, or anti-C catalytic subunits
were used.
Animal preparation. The animals in this study were han-
dled according to the animal welfare regulation of the
University Federico II of Naples, and the protocol was
approved by the animal use committee of this institution.
Fifty Wistar rats weighing 350 to 400 g (Charles River,
Calco, Italy) were included in the present study. Rats were
anesthetized with an intramuscular injection of ketamine
100 mg/kg (Sigma Chimica, Milan, Italy) and xylazine
5 mg/kg (Sigma Chimica). Angioplasty of the common
carotid artery was performed using a balloon embolectomy
catheter as previously described and well validated in our
laboratory (7,8,26–28).
Drug dosage and administration. The 8-Cl-cAMP was
randomly administered intraperitoneally in different proto-
cols: Protocol I: three times at the dose of 1.2 mg/kg at the
time of the balloon injury, three and six days later (n 5 6);
Protocol II: three times at the dose of 6 mg/kg at the time
of the balloon injury, three and six days later (n 5 7);
Protocol III: three times at the dose of 12 mg/kg at the time
of the balloon injury, three and six days later (n 5 9);
Protocol IV: two times at the dose of 12 mg/kg at the time
of the balloon injury and three days later (n 5 9). In a
control group (n 5 8), a saline solution was administered
intraperitoneally. In additional animals, either 8-Cl-cAMP,
as in Protocol III (n 5 8), or saline solution (n 5 9) was
administered, but the evaluation of neointimal thickening
was performed 28 days after balloon injury.
Toxicity. To study the 8-Cl-cAMP toxicity, laboratory
studies were performed at baseline and two weeks after drug
administration (Protocol IV) (n 5 6). Histological sections
of kidney, liver, and gastrointestinal tract were evaluated for
inflammation or necrosis.
Hemodynamic measurements. Arterial pressure and heart
rate were measured indirectly by a tail-cuff plethysmo-
graphic technique (mod. 50-0002, Harvard Apparatus,
South Natick, Massachusetts) (29).
Morphology. At the time of final experiment (14 or 28
days later), the animals were anesthetised and the carotid
arteries fixed, cut, and stained with hematoxylin-eosin. The
cross-sectional areas of EEL (external elastic membrane),
IEL (internal elastic membrane), lumen, media, and neo-
intima were measured using a computerized image analysis
system, and the ratios between neointima and media were
calculated (26). To standardize the arterial dimensions, the
data obtained were normalized by the left noninjured
carotid dimensions. Furthermore, the ratio between EEL of
right injured artery (EELdx) and EEL of left noninjured
artery (EELsx) was calculated as the arterial remodeling
index.
Assessment of VSMC proliferation rate and immunohis-
tochemistry. To assess systemic 8-Cl-cAMP administra-
tion effects on VSMC proliferation, in 11 animals vascular
balloon injury was performed as described above, and either
8-Cl-cAMP, as in Protocol IV (n 5 6), or saline solution
(n 5 5) was administered intraperitoneally. Seven days after
balloon injury, the arteries were removed and immunohis-
tochemistry for proliferating cell nuclear antigen (PCNA)
was performed as previously described (30). A PCNA index
was defined as the number of PCNA positive cells divided
by the sum of PCNA positive and negative cells and
expressed as a percentage. In an additional seven rats, the
effects of anesthesia and surgical procedure (without the
balloon injury) on VSMC proliferation were also assessed.
Statistical analysis. All data are shown as mean 6 SEM.
Statistical analysis between groups was performed by anal-
ysis of variance (ANOVA) and unpaired t test using a Systat
program (31). The Tukey test was applied to compare single
mean values. A p value ,0.05 was considered significant.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
cAMP 5 cyclic-39-59-adenosine monophosphate
DMEM 5 Dulbecco’s modified Eagle’s medium
EEL 5 external elastic membrane
FCS 5 fetal calf serum
IEL 5 internal elastic membrane
PCNA 5 proliferating cell nuclear antigen
PKA 5 protein kinase A
PTCA 5 percutaneous transluminal coronary
angioplasty
VSMCs 5 vascular smooth muscle cells
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RESULTS
The 8-Cl-cAMP induces inhibition of VSMC prolifera-
tion in vitro, down-regulation of RIa and up-regulation
of RIIb. Figure 1a shows that cAMP markedly inhibited
VSMC proliferation in a dose-dependent manner. The
biological effect of the drug was reversible, because its
removal from the culture medium resumed cell growth (data
not shown). As shown in Figure 1b, the level of RIa was
significantly reduced in VSMCs exposed to 8-Cl-cAMP.
Instead, 8-Cl-cAMP induced an enhanced level of RIIb
with no effect on the catalitic subunit. These data demon-
strated for the first time that 8-Cl-cAMP inhibits cell
growth in VSMCs by reducing RIa and enhancing RIIb
levels.
The 8-Cl-cAMP reduced neointima formation in vivo.
A reproducible neointima formation was found 14 days after
balloon injury in the control group. In the Protocol I group,
we did not observe significant differences in neointimal area
and the neointima/media ratio compared with control
group. In contrast, in animals treated with higher doses of
8-Cl-cAMP (Protocols II, III, and IV) we observed a
significant reduction of both neointima and neointima/
media ratio (Figs. 2 and 3).
In the group of animals in which we evaluated neointima
thickening 28 days after balloon injury, we observed a
significant reduction of neointima/media ratio in rats
treated as in the Protocol III (Table 1), and these data
obtained at 28 days did not significantly differ from the data
obtained at 14 days. Moreover, 8-Cl-cAMP did not induce
significant changes in arterial dimension (Table 2).
Systemic effects of 8-Cl-cAMP. No differences in arterial
pressure and heart rate were found between sham-operated
Figure 1. (a) Effects of 8-Cl-cAMP (1, 5, and 10 mmol/liter) on the
growth inhibition of rat VSMCs. Both 5 and 10 mmol/liter 8-Cl-cAMP
induced a significant inhibition of VSMC proliferation at any time. (b)
Western blot analysis in VSMCs untreated (control) or treated with
8-Cl-cAMP (1, 5, and 10 mmol/liter). The 8-Cl-cAMP induced a
significant reduction of RIa level, enhanced level of RIIb, and showed no
effect on catalytic subunit (c).
Figure 2. Bar graphs of neointima/media ratio (top panel) and neointimal
cross-sectional area (bottom panel) of common carotid arteries from rats
included in the study. The 8-Cl-cAMP and dosages administered in
Protocols II, III, and IV significantly reduced both neointimal cross-
sectional area and neointima/media ratio. *p , 0.05 vs. Controls and
Protocol I; #p , 0.05 vs. Controls and 8-Cl-cAMP Protocol I; §p , 0.05
vs. 8-Cl-cAMP Protocol III.
Figure 3. Representative histologic sections stained with hematoxylin-
eosin of common carotid arteries, removed 14 days after angioplasty, from
(a) a normal rat (no balloon injury); (b) a control rat subjected to only
balloon injury; (c) rats included in Protocol I; (d) rats included in Protocol
II; (e) rats included in Protocol III; (f) rats included in Protocol IV. The
8-Cl-cAMP reduced significantly the neointima formation after balloon
injury (c, d, e).
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animals and experimental groups. In addition, blood pres-
sure and heart rate were comparable in the different exper-
imental groups (Fig. 4). No renal function alteration was
associated with 8-Cl-cAMP administration (Table 3). The
8-Cl-cAMP did not induce any changes of kidney, hepatic,
and gastrointestinal histology (data not shown).
DISCUSSION
The major findings of the present study are that 8-Cl-
cAMP reduces the VSMC proliferation in vitro and neo-
intima formation induced by balloon injury after systemic
administration in vivo. As it has been recently shown that
8-Cl-cAMP can be used and is well tolerated in humans
(15), these data might have an important clinical relevance.
Mechanisms of restenosis. It is well known that restenosis
limits percutaneous transluminal coronary angioplasty
(PTCA) benefit occurring in 30% to 60% of patients
(32,33). Using stents has reduced the incidence of restenosis
(1,2); unfortunately, stent implantation also markedly in-
duces VSMC proliferation. In fact, neointima formation is
the only mechanism responsible for restenosis after stent
deployment (3,4), which occurs in about 20% of Benestent-
like lesions (1,2) and in about 50% of long lesions and vein
grafts (34–36). We have previously shown that local deliv-
ery of a transdominant negative H-ras gene markedly
reduces neointima formation after balloon injury in rats (7).
This finding was recently confirmed using adenovirus-
mediated gene transfer (37). The inhibition of a protein
downstream ras, MAPKK, also prevents neointima forma-
tion after balloon injury (27). Other investigators have also
shown that gene therapy could be useful (38,39); however,
at the present time, cost/benefit analysis and the possibility
of plasmid DNA stable integration in VSMC genome
leading to unwanted biological effects (13) do not allow the
use of a gene therapy approach in the clinical setting to
prevent restenosis.
We recently showed that cAMP–PKA signaling activa-
tion plays an important role in the regulation of smooth
muscle cell proliferation (8). The cAMP pathway stimula-
tion is pharmacologically feasible in the clinical setting, and
this may represent a clear advantage over the gene therapy
approach. In our previous study, the activation of cAMP–
PKA signaling was obtained using 8-Br-cAMP local ad-
ministration mediated by pluronic gel that, however, is not
clinically feasible (8). In addition, the lack of selectivity and
the high dose required for 8-Br-cAMP and other cAMP
analogues have been the major obstacle to test these drugs in
humans (15).
Mechanism of action of 8-Cl-cAMP. In the present
study, we used a potent site-selective cAMP analogue,
8-Cl-cAMP, that can be administered systemically (15–17).
It is well known that, in mammalian cells, there are two
types of cAMP-dependent protein kinases, type I and type
II, which differ from R subunits, RI and RII, and that
interact with an identical C subunit. It has been shown that
differential expression of PKAI and PKAII correlates with
cell differentiation and neoplastic transformation (40,41).
Preferential expression of PKAII is induced by treatment of
tumor cells with cAMP analogues or differentiating agents
and is typical of terminally differentiated tumors (41).
In contrast, enhanced levels of PKAI are generally found
Figure 4. Effects of 8-Cl-cAMP on systolic blood pressure (SBP) and
heart rate (HR) in rats treated with 8-Cl-cAMP (Protocol IV). Adminis-
tration of 8-Cl-cAMP did not induce significant changes in heart rate and
blood pressure.
Table 1. Morphologic Characteristic of Common Carotid
Artery of the Group of Animals Evaluated 28 Days After
Balloon Injury
Neointima (mm2) Neointima/Media
Controls 0.194 6 0.022 1.387 6 0.109
8-Cl-cAMP 12 mg/kg
(Protocol III)
0.076 6 0.042* 0.529 6 0.222*
*p , 0.005 vs. controls.
Table 2. Arterial Remodeling Among Groups in the Study
EELdx/EELsx
14 Days’ Follow-up
Controls 1.046 6 0.085
8-Cl-cAMP 1.2 mg/kg (Protocol I) 1.086 6 0.074
8-Cl-cAMP 6 mg/kg (Protocol II) 1.171 6 0.091
8-Cl-cAMP 12 mg/kg (Protocol III) 1.064 6 0.095
8-Cl-cAMP 12 mg/kg (Protocol IV) 1.066 6 0.067
28 Days’ Follow-up
Controls 1.089 6 0.089
8-Cl-cAMP 12 mg/kg (Protocol III) 1.064 6 0.078
EELdx/EELsx: ratio of cross-sectional area of right injuried artery and cross-sectional
area of left noninjuried artery.
Table 3. Effect of 8-Cl-cAMP on Laboratory Studies in Rats
After Balloon Angioplasty (Protocol IV)
Controls 8-Cl-cAMP
BUN (mg/dl) 46.24 6 2.24 43.50 6 5.45
CREA (mg/dl) 0.58 6 0.03 0.63 6 0.05
K (mmol/liter) 5.92 6 0.25 6.10 6 0.25
NA (mmol/liter) 141.2 6 4.23 139.2 6 2.50
Red cells (mm3) 7.590 3 103 6 567 3 103 7.962 3 103 6 375 3 103
Leukocyte (mm3) 13.220 6 2.955 15.050 6 3279
Platelets (mm3) 579 3 103 6 67 3 103 597 3 103 6 121 3 103
Hemoglobin (g/dl) 13.88 6 1.81 15.02 6 0.47
BUN: blood urea nitrogen; CREA: creatinine levels.
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in tumor cells (41). It has been shown that PKAI is involved
in mitogenic signaling by several growth factors (22–24).
The 8-Cl-cAMP is able to down-regulate PKAI by induc-
ing protein degradation and up-regulate RII subunit expres-
sion at the transcriptional level (21). It has been also
demonstrated that RIa down-regulation by 8-Cl-cAMP
determines growth arrest and differentiation in a wide
variety of human cancer cell lines (16,20–25). Previous
studies demonstrated that 8-Cl-cAMP induces growth
inhibition of human colon cancer line (20), of
HL60-leukemia cells (21) and of human lung carcinoma in
athymic mice (24).
In our study we observed that 8-Cl-cAMP induces an
inhibition of VSMC proliferation in vitro in a dose depen-
dent manner as we observed in vivo. To study the mecha-
nism by which 8-Cl-cAMP induces inhibition of cultured
VSMC proliferation we performed a Western blotting to
evaluate the levels of RIa, RIIb, and catalytic subunit of
PKA. The 8-Cl-cAMP induced a reduction of RIa levels,
an enhanced RIIb level, and no effects on catalitic subunits.
These data demonstrated for the first time that the inhibi-
tion of VSMC proliferation by 8-Cl-cAMP in vitro was
associated with down-regulation of RIa and up-regulation
of RIIb regulatory subunits of PKA.
Conclusions and clinical implications. Our data also
demonstrate that the systemic administration of 8-Cl-
cAMP, at the highest dose used, is able to reduce by
approximately 60% the neointimal formation after balloon
injury. More interestingly, the dose of 8-Cl-cAMP used in
the present study did not affect heart rate, blood pressure,
renal function, and histology. The 8-Cl-cAMP effect on
neointima formation was dose-dependent, and two admin-
istrations (at the time of the vascular injury and three days
later) were sufficient to reduce neointima formation after
vascular injury in our experimental model. This is an
important finding. In fact, our study demonstrates that an
agent such as 8-Cl-cAMP, administered systemically only
in two or three doses and without chronic treatment, can
prevent a very localized phenomenon such as neointimal
hyperplasia after vascular injury. Thus, our study demon-
strates for the first time that systemic administration of
8-Cl-cAMP, a new cAMP cytostatic analogue, is able to
reduce the neointima formation after vascular injury without
toxic effects. However, extreme caution should be used to
extrapolate the experimental data presented in this study
using VSMCs in culture or the rat angioplasty model to
the clinical setting. Therefore, further studies should be
performed to evaluate the effects of 8-Cl-cAMP on stent
restenosis in large animal models and eventually in
humans.
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